CalciMedica Inc. (CALC) has a key Phase 2 data readout expected in the first half of 2026.
This clinical-stage biotech develops therapies targeting calcium release-activated calcium (CRAC) channels for acute and chronic inflammatory conditions.
The company last provided updates in its third-quarter 2025 financial results, highlighting progress across its lead program, Auxora, and outlining several near-term catalysts.
Near-term Catalysts
CalciMedica's most immediate catalyst is the data readout of its Phase 2 KOURAGE trial evaluating Auxora in acute kidney injury (AKI) with respiratory failure. Enrollment in the study is ongoing, and top-line data are expected in the first half of 2026.
The company also reported positive discussions with the FDA regarding the design of a pivotal trial for acute pancreatitis (AP), with the final design anticipated in 1H 2026.
CalciMedica ended September 30, 2025, with cash, cash equivalents, and short-term investments totaling $14.1 million. The company stated that this cash position is expected to fund operations into the second half of 2026.
CALC has traded between $1.42 and $7.20 over the past year. The stock closed yesterday's trading at $5.60, up 9.16% and rose further in the after-hours to $5.78, up 3.23%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.